We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
Read MoreHide Full Article
Shares of Vir Biotechnology, Inc. (VIR - Free Report) have gained 10.7% so far this week after the company was awarded a multi-year contract by the Biomedical Advanced Research and Development Authority (“BARDA”), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response.
The multi-year contract also allows for a potential total investment of up to $1 billion for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Vir will receive an initial investment of approximately $55 million from BARDA to support the development of VIR-2482, an investigational prophylactic monoclonal antibody for seasonal and pandemic influenza viruses. A phase II pre-exposure prophylaxis study is expected to begin in the second half of 2022 with initial data anticipated in mid-2023.
BARDA can exercise 12 options in further support of the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential.
Please note that Vir signed a collaboration agreement with GlaxoSmithKline (GSK - Free Report) in 2021 for VIR-2482.
Per the terms, GSK has an exclusive option to lead post-phase II development and commercialization of VIR-2482 and will pay the company an option exercise fee of $300 million upon exercise.
Shares of Vir have plunged 49.4% in the year so far compared with the industry's 25.9% decline.
Image Source: Zacks Investment Research
The news impressed investors as Vir had earlier suffered a setback with the FDA excluding the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants in April 2022. Sotrovimab, however, currently has Emergency Use Authorization (EUA) temporary authorization or marketing approval (under the brand name Xevudy) in more than 40 countries, and remains in use outside of the United States.
Vir’s development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.
Loss estimates for BOLT have narrowed to $2.25 from $2.87 in the past 60 days. Earnings surpassed estimates in three of the trailing four quarters and missed the mark in the remaining one, the average beat being 2.39%.
Dynavax’s earnings estimates have increased to $1.73 from $1.14 for 2022 over the past 60 days. Earnings of DVAX surpassed estimates in two of the trailing four quarters and missed the mark in the remaining two, the average beat being 70.57%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
Shares of Vir Biotechnology, Inc. (VIR - Free Report) have gained 10.7% so far this week after the company was awarded a multi-year contract by the Biomedical Advanced Research and Development Authority (“BARDA”), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response.
The multi-year contract also allows for a potential total investment of up to $1 billion for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Vir will receive an initial investment of approximately $55 million from BARDA to support the development of VIR-2482, an investigational prophylactic monoclonal antibody for seasonal and pandemic influenza viruses. A phase II pre-exposure prophylaxis study is expected to begin in the second half of 2022 with initial data anticipated in mid-2023.
BARDA can exercise 12 options in further support of the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential.
Please note that Vir signed a collaboration agreement with GlaxoSmithKline (GSK - Free Report) in 2021 for VIR-2482.
Per the terms, GSK has an exclusive option to lead post-phase II development and commercialization of VIR-2482 and will pay the company an option exercise fee of $300 million upon exercise.
Shares of Vir have plunged 49.4% in the year so far compared with the industry's 25.9% decline.
Image Source: Zacks Investment Research
The news impressed investors as Vir had earlier suffered a setback with the FDA excluding the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants in April 2022. Sotrovimab, however, currently has Emergency Use Authorization (EUA) temporary authorization or marketing approval (under the brand name Xevudy) in more than 40 countries, and remains in use outside of the United States.
Vir’s development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.
Vir currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Bolt Pharmaceuticals (BOLT - Free Report) and Dynavax (DVAX - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss estimates for BOLT have narrowed to $2.25 from $2.87 in the past 60 days. Earnings surpassed estimates in three of the trailing four quarters and missed the mark in the remaining one, the average beat being 2.39%.
Dynavax’s earnings estimates have increased to $1.73 from $1.14 for 2022 over the past 60 days. Earnings of DVAX surpassed estimates in two of the trailing four quarters and missed the mark in the remaining two, the average beat being 70.57%.